User:David Gucklhorn/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==ErbB2== | ==ErbB2== | ||
- | <StructureSection load=' | + | <StructureSection load='2JWA' size='340' side='right' caption='Caption for this structure' scene=''> |
== Function == | == Function == |
Revision as of 05:16, 29 April 2022
ErbB2
|
References
- ↑ Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997 Apr 1;16(7):1647-55. doi: 10.1093/emboj/16.7.1647. PMID:9130710 doi:http://dx.doi.org/10.1093/emboj/16.7.1647
- ↑ Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990 Jun 29;61(7):1339-47. doi: 10.1016/0092-8674(90)90697-d. PMID:1973074 doi:http://dx.doi.org/10.1016/0092-8674(90)90697-d
- ↑ Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16. doi: 10.1038/nrm1962. PMID:16829981 doi:http://dx.doi.org/10.1038/nrm1962
- ↑ Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739-64. doi: 10.1146/annurev-biochem-060614-034402., Epub 2015 Jan 26. PMID:25621509 doi:http://dx.doi.org/10.1146/annurev-biochem-060614-034402
- ↑ Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739-64. doi: 10.1146/annurev-biochem-060614-034402., Epub 2015 Jan 26. PMID:25621509 doi:http://dx.doi.org/10.1146/annurev-biochem-060614-034402
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739-64. doi: 10.1146/annurev-biochem-060614-034402., Epub 2015 Jan 26. PMID:25621509 doi:http://dx.doi.org/10.1146/annurev-biochem-060614-034402
- ↑ Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov , 20. PMID:24269963 doi:http://dx.doi.org/10.1016/j.phrs.2013.11.002
- ↑ Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene. 2000 Dec 11;19(53):6093-101. doi: 10.1038/sj.onc.1203967. PMID:11156522 doi:http://dx.doi.org/10.1038/sj.onc.1203967
- ↑ Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov , 20. PMID:24269963 doi:http://dx.doi.org/10.1016/j.phrs.2013.11.002
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739-64. doi: 10.1146/annurev-biochem-060614-034402., Epub 2015 Jan 26. PMID:25621509 doi:http://dx.doi.org/10.1146/annurev-biochem-060614-034402
- ↑ Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors? Science. 1988 Jun 24;240(4860):1795-8. doi: 10.1126/science.3289120. PMID:3289120 doi:http://dx.doi.org/10.1126/science.3289120
- ↑ Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet. 1987 Jul 11;2(8550):69-72. doi: 10.1016/s0140-6736(87)92736-x. PMID:2885574 doi:http://dx.doi.org/10.1016/s0140-6736(87)92736-x
- ↑ Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15937-40. doi:, 10.1073/pnas.252640799. Epub 2002 Dec 2. PMID:12461170 doi:http://dx.doi.org/10.1073/pnas.252640799
- ↑ Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi:, 10.1073/pnas.1203201109. Epub 2012 Aug 20. PMID:22908275 doi:http://dx.doi.org/10.1073/pnas.1203201109
- ↑ Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi:, 10.1073/pnas.1516853112. Epub 2015 Oct 27. PMID:26508629 doi:http://dx.doi.org/10.1073/pnas.1516853112
- ↑ Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10. PMID:27284958 doi:http://dx.doi.org/10.1002/cncr.30102
- ↑ Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012, Dec 7. PMID:23220880 doi:http://dx.doi.org/10.1158/2159-8290.CD-12-0349
- ↑ Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N, Matsuo K, Kiura K, Miyoshi S, Matsuda F, Toyooka S. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst. 2014 Jan;106(1):djt338. doi: 10.1093/jnci/djt338. Epub 2013, Dec 7. PMID:24317180 doi:http://dx.doi.org/10.1093/jnci/djt338
- ↑ Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015 Aug;5(8):832-41. doi: 10.1158/2159-8290.CD-14-1211. PMID:26243863 doi:http://dx.doi.org/10.1158/2159-8290.CD-14-1211
- ↑ Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. J Thorac Oncol. 2017 Mar;12(3):446-457. doi: 10.1016/j.jtho.2016.11.2224. Epub, 2016 Nov 27. PMID:27903463 doi:http://dx.doi.org/10.1016/j.jtho.2016.11.2224
- ↑ Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS. Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov. 2018 Feb;8(2):174-183. doi: 10.1158/2159-8290.CD-17-0321. Epub, 2017 Dec 15. PMID:29247016 doi:http://dx.doi.org/10.1158/2159-8290.CD-17-0321
- ↑ Petrelli F, Tomasello G, Barni S, Lonati V, Passalacqua R, Ghidini M. Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. Breast Cancer Res Treat. 2017 Nov;166(2):339-349. doi: 10.1007/s10549-017-4419-x., Epub 2017 Jul 31. PMID:28762010 doi:http://dx.doi.org/10.1007/s10549-017-4419-x
- ↑ Cousin S, Khalifa E, Crombe A, Laizet Y, Lucchesi C, Toulmonde M, Le Moulec S, Auzanneau C, Soubeyran I, Italiano A. Targeting ERBB2 mutations in solid tumors: biological and clinical implications. J Hematol Oncol. 2018 Jun 25;11(1):86. doi: 10.1186/s13045-018-0630-4. PMID:29941010 doi:http://dx.doi.org/10.1186/s13045-018-0630-4
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Hristova K, Wimley WC. A look at arginine in membranes. J Membr Biol. 2011 Jan;239(1-2):49-56. doi: 10.1007/s00232-010-9323-9. Epub 2010 , Nov 25. PMID:21107547 doi:http://dx.doi.org/10.1007/s00232-010-9323-9
- ↑ Gleason NJ, Vostrikov VV, Greathouse DV, Koeppe RE 2nd. Buried lysine, but not arginine, titrates and alters transmembrane helix tilt. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1692-5. doi:, 10.1073/pnas.1215400110. Epub 2013 Jan 14. PMID:23319623 doi:http://dx.doi.org/10.1073/pnas.1215400110
- ↑ Kim C, Schmidt T, Cho EG, Ye F, Ulmer TS, Ginsberg MH. Basic amino-acid side chains regulate transmembrane integrin signalling. Nature. 2011 Dec 18;481(7380):209-13. doi: 10.1038/nature10697. PMID:22178926 doi:10.1038/nature10697
- ↑ Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, Gardon O, Tunny KA, Blucher KM, Morton CJ, Parker MW, Sierecki E, Gambin Y, Gomez GA, Alexandrov K, Wilson IA, Doxastakis M, Mark AE, Waters MJ. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014 May 16;344(6185):1249783. doi: 10.1126/science.1249783. PMID:24833397 doi:http://dx.doi.org/10.1126/science.1249783
- ↑ Gordeliy VI, Labahn J, Moukhametzianov R, Efremov R, Granzin J, Schlesinger R, Buldt G, Savopol T, Scheidig AJ, Klare JP, Engelhard M. Molecular basis of transmembrane signalling by sensory rhodopsin II-transducer complex. Nature. 2002 Oct 3;419(6906):484-7. PMID:12368857 doi:10.1038/nature01109
- ↑ Goldberg SD, Clinthorne GD, Goulian M, DeGrado WF. Transmembrane polar interactions are required for signaling in the Escherichia coli sensor kinase PhoQ. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8141-6. doi:, 10.1073/pnas.1003166107. Epub 2010 Apr 19. PMID:20404199 doi:http://dx.doi.org/10.1073/pnas.1003166107
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010
- ↑ Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub, 2018 Oct 25. PMID:30449325 doi:http://dx.doi.org/10.1016/j.ccell.2018.09.010